BG
NAVB

BlackRock Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

BlackRock Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,995
Closed -$53K – 2937
2014
Q3 		$53K Sell
1,995
-108
-5% -$2.86K ﹤0.01% 2680
2014
Q2 		$62K Sell
2,103
-324
-13% -$10.5K ﹤0.01% 2673
2014
Q1 		$90K Buy
+2,427
New +$92.1K ﹤0.01% 2581

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Group's NAVB Position: Q4 2014 in Review

BlackRock Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2014, closing a stake of 1,995 shares — an estimated $53K sold.

BlackRock Group first reported a position in NAVB in Q1 2014 and held it in 3 quarters. The position peaked at $90K in Q1 2014. 87 funds tracked by Wall St. Rank hold NAVB as of Q4 2014.

  • BlackRock Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2014 after selling out during the quarter.
  • BlackRock Group sold 1,995 Navidea Biopharmaceuticals Inc. shares in Q4 2014, an estimated $53K.
  • BlackRock Group first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2014 and held it in 3 quarters.
  • BlackRock Group's Navidea Biopharmaceuticals Inc. position peaked at $90K in Q1 2014.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2014.

Based on BlackRock Group's 13F filing for Q4 2014, filed 9 Feb 2015.